Redmile Group TOIIW Position
ExitedRedmile Group exited their position in Oncology Institute, Inc. (TOIIW) in Q2 2023, after holding the stock for 2 quarters.
The position was first reported in Q1 2023 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds TOIIW.
About Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.
Full company profile →Redmile Group TOIIW Position History
Frequently Asked Questions
Does Redmile Group own TOIIW?
No. Redmile Group exited their position in Oncology Institute, Inc. (TOIIW) in Q2 2023. They previously held the stock for 2 quarters.
How many hedge funds own TOIIW?
1 specialist biotech hedge fund currently holds TOIIW, including Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Redmile Group first buy TOIIW?
Redmile Group's position in TOIIW was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Redmile Group's TOIIW position increasing or decreasing?
Redmile Group completely exited their TOIIW position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TOIIWCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Redmile GroupPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →